When was Nimbus Therapeutics founded?

Nimbus Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.

Where is Nimbus Therapeutics located?

Nimbus Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Nimbus Therapeutics have?

As of Sep 30, 2026, the latest employee count at Nimbus Therapeutics is 101.

Is Nimbus Therapeutics a funded company?

Nimbus Therapeutics is a funded company, having raised a total of $637M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 15, 2010.

When was the latest funding round of Nimbus Therapeutics?

Nimbus Therapeutics' latest funding was a $***** Series F round on Sep 06, 2023, with participation from 10 investors.

Where does Nimbus Therapeutics rank among its competitors?

Nimbus Therapeutics ranks 31st amongst 3758 active competitors, of which 1291 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Nimbus Therapeutics?

Nimbus Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Among them, Senti Bio secured the most recent funding round in May, 2026.

Nimbus Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Nimbus Therapeutics is a series F company based in Cambridge (United States), founded in 2009 by Bruce Booth. It operates as a Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. Nimbus Therapeutics has raised $637M in funding from investors like Atlas Venture, SR One and Lightstone Ventures. The company has 3758 active competitors, including 1291 funded and 886 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and Abcellera Biologics.

Company Details

Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.

Website: www.nimbustx.com/
Social
Email ID: *****@nimbustx.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2009

Location

Cambridge, United States

Stage

Series F

Total Funding

$637M in 9 rounds

Latest Funding Round

Series F, Sep 06, 2023, $*****

Investors

Atlas Venture & 21 more

Ranked

31^st among 3758 active competitors

Employee Count

101 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3537 more

View Nimbus Therapeutics' full profile

Nimbus Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
NIMBUS DISCOVERY INC. CIN: 270296538 , United States, Active	Dec 26, 999	-	80 (As on Dec 31, 2024)	-

Nimbus Therapeutics has raised a total funding of $637M over 9 rounds. Its first funding round was on Apr 15, 2010. Its latest funding round was a Series F round on Sep 06, 2023 for $*****. 10 investors participated in its latest round. Nimbus Therapeutics has 20 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Nimbus Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 06, 2023	5713294	Series F	1089573	7126438	2701054	4083985
Sep 12, 2022	1956300	Series E	7870278	2161031	6177817	BVF Partners & 8 more
Jul 13, 2021	2906810	Series D	8715570	8386639	BVF Partners	RA Capital Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Nimbus Therapeutics's funding rounds and investors

The founders of Nimbus Therapeutics is Bruce Booth.

Here are the details of Nimbus Therapeutics' key team members:

Bruce Booth: Co-Founder of Nimbus Therapeutics and founder of 1 other company.

View details of Nimbus Therapeutics's Founder profiles and Board Members

Nimbus Therapeutics' employee count trend

Nimbus Therapeutics has 101 employees as of Sep 26. Here is Nimbus Therapeutics's employee count trend over the years:

Employee count trend for Nimbus Therapeutics

Uncover Nimbus Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nimbus Therapeutics include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of Nimbus Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
31st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	Access Industries, BVF Partners & 20 others	65/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Nimbus Therapeutics's competitors? Click here to see the top ones

Nimbus Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Nimbus Therapeutics's geography:

Free

US Tech Semi Annual Funding Report

Edition: H1, 2026 (47 Pages)

View all reports related to Nimbus Therapeutics

Media has covered Nimbus Therapeutics for a total of 10 events in the last 1 year, 5 of them have been about company updates and 2 about partnerships.